Table 1 Patient demographics and baseline disease characteristics
|  | Ipilimumab 10 mg/kg (ipi10) (n = 511) | HDI (n = 636) | Ipilimumab 3 mg/kg (ipi3) (n = 523) |
|---|---|---|---|
Age Median (range) | 52 years (18–80) | 54 years (18–83) | 54 years (19–80) |
Stage (AJCC7) | Â | Â | Â |
 IIIB | 268 (52.5%) | 331 (52.0%) | 280 (53.5%) |
 IIIC | 205 (40.1%) | 253 (39.8%) | 205 (39.2%) |
 M1a | 28(5.5%) | 34 (5.4%) | 28 (5.4%) |
 M1b | 10 (1.9%) | 18(2.8%) | 10 (1.9%) |
Sex | Â | Â | Â |
 Male | 342 (66.9%) | 395 (62.1%) | 328 (62.7%) |
 Female | 169 (33.1%) | 241 (37.9%) | 195 (37.3%) |
PS | Â | Â | Â |
 0 | 426 (83.5%) | 533 (83.8%) | 439 (84.7%) |
 1 | 85(16.5%) | 102 (16.0%) | 82 (15%) |
 Unknown/Missing | 0 | 1 (.2%) | 2 (.3%) |
Primary tumor status | Â | Â | |
 Unknown | 56 (11.0%) | 103 (16.2%) | 84 (16.1%) |
Ulceration | Â | Â | Â |
 No | 216 (42.3%) | 263 (41.4%) | 187 (35.4%) |
 Yes | 227 (44.4%) | 260 (41.5%) | 252 (46.9%) |
 Unknown (most due to unknown primary) | 68 (13.3%) | 113 (18.1%) | 84 (17.7%) |
Microscopic LN Involvement | Â | Â | |
 Yes (among IIIB/IIIC) | 233 (49.2%) | 285 (50.5%) | 247 (50.9%) |